NEW YORK, Dec. 6, 2012 /PRNewswire/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO), announced that the company is providing an update on its technology platform advancements and pipeline of ZFP Therapeutics ® as well as near- and mid-term operating goals during an Analyst and Investor Briefing being held today in New York City. The presentation, by members of Sangamo management team, will be webcast live beginning at 5:00 pm ET and can be accessed via a link on the Company's website. "We are very excited to share the progress that we have made in advancing our zinc finger DNA binding protein (ZFP) technology and ZFP Therapeutic programs, particularly in the area of monogenic diseases where we have developed a new, highly disruptive therapeutic platform for protein replacement therapies," said Edward Lanphier, president and CEO of Sangamo. "This approach can be leveraged across multiple diseases with the goal of engineering genetic cures." "Sangamo's proprietary gene-editing and gene-regulation technology is unique in its ability to generate novel, highly differentiated therapies that act at the DNA-level," stated Geoff Nichol, M.B., Ch.B ., Sangamo's executive vice president of research and development. "This capability enables us to address the source of a wide variety of genetic diseases and potentially cure them. In addition to two ongoing Phase 2 clinical trials of SB-728-T, which may afford a functional cure for HIV/AIDS, we have a rich pipeline of preclinical programs. These include ZFP Therapeutics for hemophilia and Huntington's disease, which we are developing in collaboration with Shire, as well as Sangamo's programs in hemoglobinopathies (sickle cell disease and beta-thalassemia) and lysosomal storage diseases (LSDs). Based upon our ZFP Therapeutic approach and the disease targets that we have selected, we expect to file up to seven new INDs by 2015." "Commercially, our business model has enabled us to monetize the value of our ZFP technology platform and maintain a strong balance sheet through partnerships with Dow AgroSciences in plant agriculture and Sigma-Aldrich Corporation in life science research reagents, while making significant progress in advancing our ZFP Therapeutics programs," continued Mr. Lanphier. "Beyond our very significant collaboration with Shire, we plan to establish additional high-value strategic partnerships around selected therapeutic programs at points of realizable value inflection while continuing to advance proprietary programs and increasingly forward integrate."